NCT06601192 - A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

February 2, 2025

Study Completion Date

February 25, 2025

Conditions

RSV InfectionQTc Interval

Interventions

DRUG

zelicapavir (therapeutic dose)

Subjects will receive zelicapavir (TD) once per treatment period.

DRUG

zelicapavir (supratherapeutic dose)

Subjects will receive zelicapavir (SD) once per treatment period.

DRUG

Placebo

Subjects will receive zelicapavir matching placebo once per treatment period.

DRUG

moxifloxacin

Subjects will receive moxifloxin once per treatment period.

Trial Locations (2)

ICON, Lenexa

ICON Early Phase, LLC, San Antonio